Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- The lancet. Gastroenterology & hepatology
- Publicado em
- 7 mar 2023
- Citações
- 37
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Jason A Tye-Din, A James M Daveson, Gautam Goel, Kaela E Goldstein, Holly L Hand, Kristin M Neff, Alina Popp, Juha Taavela, Markku Mäki, Jorma Isola et al.
Descritores MeSH
- Celiac Disease
- Female
- Glutens
- Humans
- Immunotherapy
- Male
- Peptide Fragments
- Adult
- Peptides
Veja também
Estudos relacionados
- A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease
- Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review
- Stool Gluten Peptide Detection Is Superior to Urinary Analysis, Coeliac Serology, Dietary Adherence Scores and Symptoms in the Detection of Intermittent Gluten Exposure in Coeliac Disease: A Randomised, Placebo-Controlled, Low-Dose Gluten Challenge Study
- The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment
- HDAC5 sintoniza competência efetora em CD8+ humanos diferenciados Células T através de um eixo ACTL6A-IRF4